SAN DIEGO, Jan. 22 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. , a biopharmaceutical research and development company focused on commercializing anticancer and antiviral therapies, announced today that Brian M. Culley, Chief Business Officer, will present a corporate overview at the American Stock Exchange’s First Annual Healthcare Investor Conference at the Fairmont Copley Plaza in Boston, on Thursday February 8th at 8:35am EST. For more information about this conference, visit http://guest.cvent.com/i.aspx?5S,M3,c6a42e00-40bb-4e56-a650-4ab741509a38.
A live web cast of the presentation will be available and can be accessed via the “Investors” section of the Company’s corporate web site at http://www.adventrx.com under “Events.” After the live web cast, the presentation will remain available on the Company’s web site for 14 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing anticancer and antiviral therapies that improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. The Company’s lead product candidate, CoFactor (ANX-510), is currently being tested in a pivotal Phase III study for metastatic colorectal cancer in the US. More information can be found on the Company’s corporate web site at http://www.adventrx.com.
About The American Stock Exchange
The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 138 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX’s press releases and public filings with the Securities and Exchange Commission. ADVENTRX’s public filings with the Securities and Exchange Commission are available at www.sec.gov. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.
ADVENTRX Pharmaceuticals, Inc.
CONTACT: Ioana C. Hone of ADVENTRX Pharmaceuticals, Inc., +1-858-552- 0866
Web site: http://www.adventrx.com//
Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html/
